Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

171.50 -4.24 (-2.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

56 57 Next >

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...

Via Benzinga

Analyst Ratings for Biogen ↗

October 11, 2023

Via Benzinga

LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly ↗

October 10, 2023

Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC: ESALY)/ Biogen Inc's (NASDAQ:

Via Benzinga

Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio ↗

October 07, 2023

Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical stage biologic antibody drugs for autoimmune and allergic diseases. Meanwhile, Biogen...

Via Talk Markets

Topics Initial Public Offering

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today ↗

October 03, 2023

Via Benzinga

Is Biogen Stock a Buy Now? ↗

September 28, 2023

It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.

Via The Motley Fool

(BIIB) - Analyzing Biogen's Short Interest ↗

September 20, 2023

Via Benzinga

An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8 ↗

October 05, 2023

Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attention to gold miners”:

Via Benzinga

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

September 29, 2023

From Biogen Inc.

Via GlobeNewswire

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Biogen Completes Acquisition of Reata Pharmaceuticals

September 26, 2023

From Biogen Inc.

Via GlobeNewswire

$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

September 15, 2023

Via Benzinga

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

September 04, 2023

Via Benzinga

Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗

September 25, 2023

Benzinga

Via Benzinga

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi ↗

September 25, 2023

Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

(BIIB) - Analyzing Biogen's Short Interest ↗

September 01, 2023

Via Benzinga

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

September 25, 2023

From Biogen Inc.

Via GlobeNewswire

California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims ↗

September 22, 2023

California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing...

Via Benzinga

Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy? ↗

September 09, 2023

Buying a biotech is a good move, but it might not be enough to entice investors.

Via The Motley Fool

7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth ↗

September 07, 2023

Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.

Via InvestorPlace

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst ↗

September 06, 2023

B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a

Via Benzinga

3 Healthcare Stocks to Sell in September Before They Crash & Burn ↗

September 06, 2023

The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗

September 06, 2023

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...

Via Benzinga

Biogen Appoints Jane Grogan as Head of Research

September 06, 2023

From Biogen Inc.

Via GlobeNewswire

The 3 Best Biotech Stocks to Buy Now: September 2023 ↗

September 04, 2023

With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.

Via InvestorPlace

Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment ↗

August 31, 2023

The company is now focusing on its launch in postpartum depression.

Via Investor's Business Daily

The 7 Most Promising Momentum Stocks to Own Now ↗

August 31, 2023

These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.

Via InvestorPlace

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.